AVITA Medical, Inc.RCEL
Key ratios
FCF / Sales
-32.5%TTM
2025
-45.0%2024
-90.4%2023
-78.6%
Net margin
-57.0%TTM
2025
-67.9%2024
-96.3%2023
-70.6%
ROA
-41.6%TTM
2025
-39.1%2024
-37.0%2023
-25.4%
ROE
-1746.3%TTM
2024
-231.0%2023
-52.9%
Revenue growth
1.0%TTM
2025
11.5%2024
28.1%2023
45.7%
Recent news
AVITA Medical Announces Positive PermeaDerm Study Results Showing 70% Economic Advantage over Allograft
AVITA Medical to Host Investor Webinar Briefing
Track RCEL in your journal
Save it to a watchlist, run a reverse DCF, and keep your notes on the company in one place. Free to start.
Figures are sourced from third parties and shown for research only. They may be delayed or incomplete, and nothing on this page is investment advice or a recommendation to buy or sell. Read the full disclaimer